The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of the additive bis(2-ethylhexyl)cyclohexane-1,4-dicarboxylate (DEHCH), food contact materials (FCM) substance No 1079, which is intended to be used as plasticizer in poly(vinyl chloride) (PVC) film sat up to 25% w/w in contact with aqueous, acidic and low-alcohol foods for long-term storage at room temperature or below (refrigerated and frozen). The films are not intended for use in reheating food. Under the tested conditions, the substance migrated up to 0.034 mg/kg from samples of PVC films manufactured with 25% w/w DEHCH. Based on the reported in vitro and in vivo genotoxicity studies, the Panel concluded that the substance does not raise a concern for genotoxicity. Based on the provided toxicokinetic study, the Panel concluded that there is uncertainty on the potential for accumulation of the substance in humans. No adverse effects were observed up to the highest tested dose of 1,000 mg/kg body weight (bw) per day in repeated dose toxicity studies. Nevertheless, these data do not remove the uncertainty on the potential for accumulation in humans. Therefore, the CEP Panel concluded that the substance bis(2-ethylhexyl)cyclohexane-1,4-dicarboxylate is not of safety concern for the consumer, if it is used in poly(vinyl chloride) (PVC) in contact with foods for which simulants A (10% ethanol) and B (3% acetic acid) are assigned, for long-term storage at room temperature or below. The migration of the substance should not exceed 0.050 mg/kg food.
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Note:
The full opinion will be published in accordance with Article 10(6) of Regulation (EC) No 1935 No /2004 once the decision on confidentiality, in line with Article 20(3) of the Regulation, will be received from the European Commission. The following information has been provided under confidentiality and it is redacted awaiting the decision of the Commission: cis/trans ratio and manufacture details of the substance, percentage of residual impurity, tested concentrations of the in vitro mammalian cell gene mutation test, details of the study report on the toxicokinetic testing. This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made. According to this procedure, the industry submits applications to the Member States' competent authorities which transmit the applications to the European Food Safety Authority (EFSA) for their evaluation.
In this case, EFSA received an application from the German Competent Authority (Bundesamt f € ur Verbraucherschutz und Lebensmittelsicherheit, BVL), requesting the evaluation of the substance bis(2-ethylhexyl)cyclohexane-1,4-dicarboxylate, with the Chemical Abstracts Service (CAS) number 84731-70-4 and the FCM substance No 1079. The dossier was submitted on behalf of Hanwha Chemical Co.
According to Regulation (EC) No 1935/2004 of the European Parliament and of the Council on materials and articles intended to come into contact with food, EFSA is asked to carry out an assessment of the risks related to the intended use of the substance and to deliver a scientific opinion.
2.
Data and methodologies
Data
The applicant has submitted a dossier in support of their application for the authorisation of bis(2-ethylhexyl)cyclohexane-1,4-dicarboxylate to be used in FCM.
Additional information was provided by the applicant during the assessment process in response to requests from EFSA sent on 30 November 2018 (see 'Documentation provided to EFSA').
Data submitted and used for the evaluation are:
Non-toxicological data and information 
Methodologies
The assessment was conducted in line with the principles laid down in Regulation (EC) No 1935/2004 on materials and articles intended to come into contact with food. This Regulation underlines that applicants may consult the Guidelines of the Scientific Committee on Food (SCF) for the presentation of an application for safety assessment of a substance to be used in FCM prior to its authorisation (European Commission, 2001), including the corresponding data requirements. The dossier that the applicant submitted for evaluation was in line with the SCF guidelines (European Commission, 2001).
The methodology is based on the characterisation of the substance that is the subject of the request for safety assessment prior to authorisation, its impurities and reaction and degradation products, the evaluation of the exposure to those substances through migration and the definition of minimum sets of toxicity data required for safety assessment.
To establish the safety from ingestion of migrating substances, the toxicological data indicating the potential hazard and the likely human exposure data need to be combined. Exposure is estimated from studies on migration into food or food simulants and considering that a person may consume daily up to 1 kg of food in contact with the relevant FCM.
As a general rule, the greater the exposure through migration, the more toxicological data are required for the safety assessment of a substance. Currently there are three tiers with different thresholds triggering the need for more toxicological information as follows: a) In case of high migration (i.e. 5-60 mg/kg food), an extensive data set is needed. b) In case of migration between 0.05 and 5 mg/kg food, a reduced data set may suffice. c) In case of low migration (i.e. < 0.05 mg/kg food), only a limited data set is needed.
More detailed information on the required data is available in the SCF guidelines (European Commission, 2001).
The assessment was conducted in line with the principles described in the EFSA Guidance on transparency in the scientific aspects of risk assessment (EFSA, 2009) and considering the relevant guidance from the EFSA Scientific Committee.
Assessment
According to the applicant, 2 bis(2-ethylhexyl)cyclohexane-1,4-dicarboxylate (DEHCH) is intended to be used as plasticizer in poly(vinyl chloride) (PVC) films at up to 250 mg/g (25% w/w) in contact with aqueous, acidic and low-alcohol foods for long-term storage at room temperature or below (refrigerated and frozen). The films are not intended for use in reheating food.
The substance has not been evaluated by the SCF or the EFSA in the past. Bis(2-ethylhexyl)cyclohexane-1,4-dicarboxylate (DEHCH) has a molecular mass of 396.6 Dalton (Da). It is virtually insoluble in water (0.047 mg/L at 20°C) and highly liposoluble (Log Po/w = 8.84). Thermogravimetric analysis (TGA) demonstrated thermostability up to 300°C, which is above the temperatures used to process PVC.
Non-toxicological data
DEHCH is a mixture of two cis/trans isomers (mean ratio: ), produced by of bis(2-ethylhexyl)benzene-1,4-dicarboxylate (DEHT). The purity of the substance is > 99%. Residual DEHT (CAS No 6422-86-2;FCM No 798, total specific migration limit, SML(T) 60 mg/kg) is given as impurity at .
Hydrolytic stability was tested in 10% ethanol and 3% acetic acid. 4 The substance DEHCH remained unchanged after 10 days at 40°C.
Specific migration 5
Samples of PVC films (0.012 mm thickness) manufactured with 25% w/w DEHCH were submitted to specific migration tests for 10 days at 40°C with 10% ethanol and 3% acetic acid (simulants A and B in Regulation (EU) No 10/2011). 6 After heptane extraction of the migration solutions, DEHCH, DEHT and 2-ethylhexanol (2-EH, CAS No 104-76-7; FCM No 209, specific migration limit, SML 30 mg/kg) were analysed by Gas Chromatography-Mass Spectrometry-Selected Ion Monitoring (GC-MS-SIM). Migration of DEHCH, DEHT and 2-EH measured in 10% ethanol was 0.034 mg/kg, < 0.0085mg/kg and 0.0060 mg/kg, respectively. Migration in 3% acetic acid was 0.023 mg/kg, < 0.0085 mg/kg and 0.028 mg/kg, respectively.
The migration of DEHT and 2-EH, which are substances listed in Regulation (EU) No 10/2011, was therefore well below their respective migration limits (SML(T) 60 mg/kg and SML 30 mg/kg).
3.2.
Toxicological data 3.2.1. Genotoxicity 3.2.1.1. Bacterial reverse mutation test 7 DEHCH (> 99% purity) was tested in a bacterial reverse mutation test (Ames test) in Salmonella typhimurium (TA98, TA100, TA1535, TA1537) and Escherichia coli (WP2uvrA). The assay was performed following Organisation for Economic Co-operation and Development OECD Test Guideline 471 (1997) and Good Laboratory Practice, using the plate incorporation method and ethanol as solvent for the test substance. In the preliminary dose-range finding study (4-2,500 lg/plate), no cytotoxicity was observed at any dose level; precipitation was observed at doses ≥ 500 lg/plate. The main experiment was performed twice, using triplicate plates with 15.6, 31.3, 62.5, 125, 250 and 500 lg/ plate, in the presence and absence of metabolic activation (S9 mix).
In both experiments, DEHCH did not induce reproducible and/or dose-related increases of revertants. Positive controls elicited the expected positive response. Based on these findings, the Panel concluded that the substance is not mutagenic under the conditions of this study.
3.2.1.2.
In vitro mammalian cell gene mutation test 8 DEHCH (> 99% purity) was tested in an in vitro cell gene mutation assay (in vitro mammalian cell mutation test in mouse lymphoma cell L5178Y/TK +/-). The assay was performed following OECD Test Guideline 490 (2015) and Good Laboratory Practice. In the first experiment, cells were treated for 4 h in the presence and absence of metabolic activation; in the repeat experiment, cells were treated for 24 h without metabolic activation (S9 mix).
In a range-finding preliminary test in the presence (4 h treatment) and absence (4 h and 24 h treatment) of metabolic activation, no toxic effect (< 50% survival) was observed up to the highest tested dose of 2,000 lg/mL. The dose selection for the main experiments was based on precipitation of the test item at the end of the treatment period: in the first experiment, tested concentrations were lg/mL with and without metabolic activation; in the second experiment, tested concentrations were lg/mL. Two parallel cultures were used per test concentration. Ethanol was used as solvent. In both experiments the mutation frequency in treated cultures did not exceed the threshold of 126 (global evaluation factor according to OECD Test Guideline 490) above the corresponding solvent control at any tested concentration. No relevant change in the ratio of small vs. large colonies was observed up to the maximal tested concentration.
Overall, the Panel concluded that DEHCH is not mutagenic in the mouse lymphoma assay under the conditions of this study.
3.2.1.3. In vitro mammalian chromosomal aberration test 9 DEHCH (> 99% purity) was tested in an in vitro chromosome aberration test in Chinese hamster lung cells (CHL) following OECD Test Guideline 473 (1997) and Good Laboratory Practice. In the preliminary dose range-finding study, doses from 9.8 to 2,500 lg/mL were tested. Ethanol was used as solvent. No cytotoxicity was observed up the highest tested dose; precipitation of the test item was observed at concentrations ≥ 312 and ≥ 78.1 lg/mL in the presence and absence of metabolic activation (S9 mix), respectively. Based on these findings, in the main experiment, DEHCH was tested in the presence of metabolic activation for 6 hours at 39.1, 78.1, 156.3 and 312.5 lg/mL, and in the absence of metabolic activation for 6 h and 22 h, respectively, at 9.8, 19.5, 39.1, and 78.1 lg/mL. Chromosomal aberrations were analysed scoring 100 metaphases per tested concentration. There was no significant increase in the number of metaphases with structural aberrations at any tested concentration. In the positive control groups, there were significant increases in the number of aberrant metaphases.
The Panel concluded that DEHCH is not clastogenic under the tested conditions of this study. However, the Panel noted that the number of scored metaphases, although acceptable at the time the study was performed in 2009, is lower than currently recommended (OECD Test Guideline 473, 2016).
3.2.1.4. In vivo mammalian erythrocyte micronucleus test 10 DEHCH (> 99% purity) was tested in the in vivo mammalian erythrocyte micronucleus test. The test was performed according to OECD Test Guideline 474 (1997) and Good Laboratory Practice. DEHCH was dissolved /suspended in corn oil. It was administered by gavage twice at 24 h interval to 7-weekold male and female CD1(ICR) mice at 500, 1,000 and 2,000 mg/kg body weight (bw), using six animals per sex and dose. Micronucleated polychromatic erythrocytes (MNPCE) were counted in 2,000 polychromatic erythrocytes (PCE) per animal. There was no statistically significant increase of MNPCEs at any dose compared to the controls.
No effect was observed on the ratio of PCE to the sum of PCE and normochromatic erythrocytes (NCE), indicating absence of bone marrow exposure. However, the bioavailability of the test item after single oral gavage administration was demonstrated in a toxicokinetic study in rats (see section 3.2.2).
In conclusion, the Panel evaluated DEHCH as not clastogenic and aneugenic in vivo under the test conditions of this study.
Conclusions on genotoxicity
DEHCH was tested in a battery of in vitro and in vivo genotoxicity assays, performed according to Good Laboratory Practice (GLP) and the OECD guidelines. DEHCH was negative in adequately conducted bacterial and mammalian cell gene mutation tests and in the in vivo micronucleus test; negative results were obtained in a limited in vitro chromosomal aberration assay. The Panel noted that the battery of studies available is not aligned with the more recent test requirements, as an in vitro micronucleus assay is missing (EFSA Note for Guidance, 2017), however, the data package available is considered sufficient to rule out a genotoxic concern for DEHCH, since all relevant genotoxicity end-points (gene mutation, clastogenicity and aneugenicity) were adequately addressed.
Toxicokinetic
A toxicokinetic study 11 was performed according to GLP and OECD Test Guideline 417 (2013) in Sprague-Dawley (SD) rats with non-radiolabelled DEHCH (> 99% purity), after single oral administration by gavage at 60 mg/kg bw (low dose)
